505318753 02/07/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5365534

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ALLAN JORDAN	12/10/2018
REBECCA NEWTON	12/10/2018
BOHDAN WASZKOWYCZ	12/14/2018
JONATHAN M. SUTTON	12/10/2018
GEORGE HYND	12/10/2018
SILVIA PAOLETTA	12/11/2018
EUAN A. FORDYCE	12/11/2018

RECEIVING PARTY DATA

Name:	CANCER RESEARCH TECHNOLOGY LIMITED
Street Address:	ANGEL BUILDING
Internal Address:	407 ST JOHN STREET
City:	LONDON
State/Country:	UNITED KINGDOM
Postal Code:	EC1V 4AD

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16093858

CORRESPONDENCE DATA

Fax Number: (617)832-7000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (617) 832-1754

Email: patentdocketing@foleyhoag.com, cle@foleyhoag.com

Correspondent Name: FOLEY HOAG LLP

Address Line 1: 155 SEAPORT BOULEVARD

Address Line 4: BOSTON, MASSACHUSETTS 02210-2600

ATTORNEY DOCKET NUMBER:	HGX-07301
NAME OF SUBMITTER:	CAREN LE
SIGNATURE:	/CAREN LE/

PATENT 505318753 REEL: 048269 FRAME: 0354

DATE SIGNED:	02/07/2019
Total Attachments: 9	
source=HGX07301Assignment#page1.t	if
source=HGX07301Assignment#page2.t	if
source=HGX07301Assignment#page3.t	if
source=HGX07301Assignment#page4.t	if
source=HGX07301Assignment#page5.t	if
source=HGX07301Assignment#page6.t	if
source=HGX07301Assignment#page7.t	if
source=HGX07301Assignment#page8.t	if
source=HGX07301Assignment#page9.t	if

PATENT REEL: 048269 FRAME: 0355

ASSIGNMENT

WHEREAS, we, Allan Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, and Euan Alexander Fraser Fordyce, have invented one or more inventions described in an application for Letters Patent of the United States, entitled HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS the specification of which:

[]	is being execute	d herewith; and is a	bout to be filed in the United St	ates Patent Office;	
[x]	was filed on	October 15, 2018	as U.S. Application No.	16/093,858	;
Ú	was filed on		as PCT Application No	;	
	was patented on	:	as U.S. Patent No.		

WHEREAS, Cancer Research Technology Limited, (hereignafter "ASSIGNEE"), a corporation organized and existing under the laws of ______, having principal offices at Angel Building, 407 St John Street, LONDON, ECIV 4AD, UNITED KINGDOM, desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention(s) as described in said application, together with our entire right, title and interest in and to said application and such Letters Patent as may issue thereon, and any substitution, reissue, continuation, divisional, revival and foreign counterparts thereof and including the right to claim priority under any applicable statute, treaty or convention based on said application; said invention(s), application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, all choses in action pertaining to the applications or Letters Patent including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications or Letters Patent. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of

B4894513.1

ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention(s) to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of substitution, reissue, divisional, continuation or revival applications and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention(s) or any application or patent directed thereto may be involved;

AND, we do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

Inventor:	Allan Nordan	Date:	10/12/13
Address:	c/o Cancer Research UK Manchester Institute		
	The University of Manchester		
	Wilmslow Road		
	MANCHESTER M20 4BX;		
	UNITED KINGDOM		S & 2
Witness:		Date:	10/12/18
	7		
Print Nam	ie: Kal Lawrence		

- 2 -

Attorney Docket No. HGX-07301

Inventor:	(Newlow	
	Rebecca Newton	

Address: c/o Cancer Research UK Manchester

Institute

The University of Manchester

Wilmslow Road

MANCHESTER M20 4BX;

UNITED KINGDOM

Print Name: BEN 11009357

Date: 10/12/18.

<u>-3</u> -

Attorney Docket No. HGX-07301

Inventor:	Wylens -	Date:	14/12/18

Bohdan Waszkowycz

Address: c/o C4X Discovery PLC

Manchester One 53 Portland Street

MANCHESTER M1 3LD UNITED KINGDOM

Witness: 14/12/18

Print Name: GRASME 71+0M>ON

U.S. Application No. 16/093, 858		Attorney Docket No. HGX-0730			101		
aa. J	nventor;	Jonathan Mark Sutton	Date:		0 1 '	2 201	8
A	ddress:	c/o Charles River Discovery 8-9 Spire Green Centre HARLOW CM19 5TR UNITED KINGDOM					
W.	/itness;	7. /	Date:	10	DEC	2018	

Print Name: Tosy MULLINS

-5-

Attorney Docket No. HGX-07301

Inventor:

George Hynd

Date: 10th Qc 2018

Address: c/o Charles River Discovery

8-9 Spire Green Centre HARLOW CM19 5TR UNITED KINGDOM

Witness:

Date: 10th DEC 2018

Print Name: SANJEET SEHMI

-6-

B4894513.1

PATENT

REEL: 048269 FRAME: 0361

Attorney Docket No. HGX-07301

Inventor: Jihra Rowletto
Silvia Paoletta

Date: 11/12/2018

Address: c/o Sygnature Discovery Limited

BioCity, Pennyfoot Street NOTTINGHAM NGI 1GF UNITED KINGDOM

SASIGN Date: M. Dec 2018

Witness:

Print Name: STEVE A. ST-GALLAY

÷7.*

B4894513.1

PATENT REEL: 048269 FRAME: 0362

Attorney Docket No. HGX-07301

Date: Illi2/18

Address: c/o Sygnature Discovery Limited

BioCity, Pennyfoot Street NOTTINGHAM NGI IGF UNITED KINGDOM

Witness: Crown o'Reilly Date: 11/2/18

Print Name: Crown o'Reilly

-8-

ACKNOWLEDGEMENT OF ASSIGNEE:

	acknowledge the foregoing executed Assignmen logy Limited,	t on behalf	of Cancer Research	
T PCHHO	A STATE OF THE STA		- 1 1 m	
By:	Jayen lande	Date:	11/1/19	
Name:	Dr Angus Lauder			
Title:	Associate Director			

B4894513.1

PATENT REEL: 048269 FRAME: 0364